These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11915004)

  • 21. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low frequency of hypersensitivity reactions to abacavir in HIV infected patients in a referral center in Bahia, Brazil.
    Barreto RG; Brites C
    Braz J Infect Dis; 2019; 23(4):268-270. PubMed ID: 31374183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 24. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.
    El-Sahly HM
    AIDS; 2004 Jan; 18(2):359-60. PubMed ID: 15075569
    [No Abstract]   [Full Text] [Related]  

  • 27. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir.
    Cutrell AG; Hernandez JE; Fleming JW; Edwards MT; Moore MA; Brothers CH; Scott TR
    Ann Pharmacother; 2004 Dec; 38(12):2171-2. PubMed ID: 15536137
    [No Abstract]   [Full Text] [Related]  

  • 28. Kawasaki-like syndrome: abacavir hypersensitivity?
    Toerner JG; Cvetkovich T
    Clin Infect Dis; 2002 Jan; 34(1):131-3. PubMed ID: 11731962
    [No Abstract]   [Full Text] [Related]  

  • 29. Severe hypersensitivity reactions following reintroduction of abacavir.
    AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447
    [No Abstract]   [Full Text] [Related]  

  • 30. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
    Kessler HA; Johnson J; Follansbee S; Sension MG; Mildvan D; Sepulveda GE; Bellos NC; Hetherington SV
    Clin Infect Dis; 2002 Feb; 34(4):535-42. PubMed ID: 11797183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiological risk factors for hypersensitivity reactions to abacavir.
    Easterbrook PJ; Waters A; Murad S; Ives N; Taylor C; King D; Vyakarnam A; Thorburn D
    HIV Med; 2003 Oct; 4(4):321-4. PubMed ID: 14525543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reasons for early abacavir discontinuation in HIV-infected patients.
    Peyriere H; Guillemin V; Lotthe A; Baillat V; Fabre J; Favier C; Atoui N; Hansel S; Hillaire-Buys D; Reynes J
    Ann Pharmacother; 2003 Oct; 37(10):1392-7. PubMed ID: 14519040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
    Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
    Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
    de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS
    AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818
    [No Abstract]   [Full Text] [Related]  

  • 37. Anaphylaxis after rechallenge with abacavir.
    Walensky RP; Goldberg JH; Daily JP
    AIDS; 1999 May; 13(8):999-1000. PubMed ID: 10371187
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
    Shapiro M; Ward KM; Stern JJ
    AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comment: Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Oct; 42(10):1519-20; author reply 1520-1. PubMed ID: 18780810
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.